{
    "root": "313f265b-801f-f75d-e063-6294a90aa10d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Spironolactone",
    "value": "20250326",
    "ingredients": [
        {
            "name": "CALCIUM SULFATE DIHYDRATE",
            "code": "4846Q921YM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32583"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MINT",
            "code": "FV98Z8GITP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SPIRONOLACTONE",
            "code": "27O7W4T232",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9241"
        }
    ],
    "indications": {
        "text": "spironolactone aldosterone antagonist indicated : treatment nyha class iii-iv heart failure reduced ejection fraction increase survival , manage edema , reduce need hospitalization heart failure ( 1.1 ) . add-on therapy treatment hypertension , lower blood pressure . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions ( 1.2 ) . management edema adult patients cirrhotic edema responsive fluid sodium restrictions setting nephrotic syndrome treatment underlying disease , restriction fluid sodium intake , diuretics produce inadequate response ( 1.3 ) . treatment primary hyperaldosteronism : ( 1.4 ) short-term preoperative treatment long-term maintenance patients discrete aldosterone-producing adrenal adenomas candidates surgery patients bilateral micro macronodular adrenal hyperplasia",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "primary hyperaldosteronism (DOID:446)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_446"
            },
            {
                "text": "adenomas (DOID:657)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_657"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "heart failure : initiate treatment 25 mg daily ( 2.2 ) . hypertension : initiate treatment 25 100 mg daily either single divided doses ( 2.3 ) . edema : initiate therapy hospital setting titrate slowly . recommended initial daily dose 100 mg single divided doses ( 2.4 ) . primary hyperaldosteronism : initiate treatment 100 400 mg preparation surgery . patients unsuitable surgery lowest effective determined individual patient ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "primary hyperaldosteronism (DOID:446)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_446"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "spironolactone 25 mg tablets round , white off-white , convex , coated , debossed 852 one side debossed \u201c \u201d side , supplied : ndc : 70518-3625-00 ndc : 70518-3625-01 ndc : 70518-3625-02 ndc : 70518-3625-03 packaging : 30 1 blister pack packaging : 100 1 bottle plastic packaging : 90 1 bottle plastic packaging : 30 1 bottle plastic store 77\u00b0f ( 25\u00b0c ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "spironolactone contraindicated patients : hyperkalemia addison \u2019 disease concomitant eplerenone",
    "indications_original": "Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia",
    "contraindications_original": "Heart Failure: Initiate treatment at 25 mg once daily ( 2.2 ). Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses ( 2.3 ). Edema:\u00a0 Initiate therapy in a hospital setting and titrate slowly.\u00a0 The recommended initial daily dose is 100 mg in single or divided doses ( 2.4 ). Primary hyperaldosteronism:\u00a0 Initiate treatment at 100 to 400 mg in preparation for surgery.\u00a0 In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient ( 2.5 ).",
    "warningsAndPrecautions_original": "Spironolactone 25 mg tablets are round, white to off-white, convex, coated, debossed with 852 on one side and debossed with \u201cO\u201d on the other side, supplied as:\n                  \n                  NDC: 70518-3625-00\n                  NDC: 70518-3625-01\n                  NDC: 70518-3625-02\n                  NDC: 70518-3625-03\n                  \n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store below 77\u00b0F (25\u00b0C).\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Spironolactone is contraindicated in the patients with:\n                  \n                     Hyperkalemia\n                     Addison\u2019s disease\n                     Concomitant use of eplerenone",
    "drug": [
        {
            "name": "Spironolactone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9241"
        }
    ]
}